Johnson Fistel Begins Investigation into DexCom Following a Significant Drop in the Company’s Stock
Shareholder rights law firm Johnson Fistel, LLP is investigating whether DexCom, Inc. (NASDAQ: DXCM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased DexCom securities? If you purchased securities and suffered losses on your investment, join our investigation now:
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
What is Johnson Fistel investigating? On July 25, 2024, after the closure of market trading, DexCom issued a press release announcing its financial results for the second quarter of 2024. The Company reported revenue figures amounting to $1.004 billion. However, the press release conveyed that the Company’s performance did not meet its established high standards of execution. Furthermore, DexCom revised its revenue guidance for the full fiscal year of 2024, projecting a revenue range between $4 billion and $4.05 billion. This adjustment was attributed to “certain unique items impacting 2024 seasonality,” which have been identified as factors influencing the Company’s financial outlook.
Following this news, DexCom stock was trading down 39% during pre-market trading on July 26, 2024.